ONCYOncolytics BiotechSigning up patients
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Ras-mutated Metastatic Colorectal Cancer · mCRC · MSS Metastatic Colorectal Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Apr 30, 2026
- Main results expected
- Aug 30, 2027
- Fully finished
- Apr 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR)
Measured over: At week 8
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07446322 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC